1. Are Combinations the Solution: Perspectives on Combination Immunotherapy

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Immunotherapy: Paradigm on the Rise

4. MOA of Inhibitors on PD-1 Pathway

5. FDA Approved PD-1/PD-L1 Inhibitors

6. Toxicity With PD-1/PD-L1 Inhibitors

7. Predictive Biomarkers Are Lacking

8. PD-1 and CTLA-4 Inhibition in Melanoma

9. CheckMate 069

10. What About Other Tumors?

11. CheckMate 012

12. Durvalumab/Tremelimumab in NSCLC

13. Toxicity in a Broader Population

14. Immunotherapy Is Not Chemotherapy

15. Immunotherapy/Immunotherapy Summary

16. Chemoimmunotherapy

17. KEYNOTE 021

18. KEYNOTE 024

19. Chemotherapy/Immunotherapy Summary

20. Overcoming Challenges of Targeted Therapies

21. PD-1/BRAF/MEK Inhibition in Melanoma

22. PD-1/EGFR Inhibition in NSCLC

23. TATTON Results: EGFR/PD-L1 Inhibition

24. Is Immunotherapy the Right Approach?

25. Mutational Load in Never Smokers

26. Targeted Therapy/Immunotherapy Summary

27. Overall Conclusions

28. Abbreviations